- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06206564
Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants (ART-AIN IIB-2)
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Ointment for the Treatment of HIV-negative Patients With Anal High-grade Squamous Intraepithelial Lesions (Anal HSIL)
Study Overview
Status
Intervention / Treatment
Detailed Description
Eligible participants in this study are randomized 2:1 to receive either artesunate or placebo ointment for the treatment of anal HSIL. Both groups receive four 5-day cycles of ointment, at weeks 0, 2, 4, and 6. Participants are followed closely with anoscopy or high resolution anoscopy (HRA) at weeks 8, 18, 30, and 42. After the week 18 HRA visit, participants who have at least partial response will be followed with HRA at week 30.
Participants who are found to be non-responders at week 18 will undergo standard of care ablation.
Participants who are found to have anal HSIL at weeks 30 or 42 will be followed according to standard of care procedures.
Primary Objective: To evaluate the complete and partial histopathologic response to four 5-day cycles of artesunate ointment in adult patients with biopsy-proven HPV-associated intra-anal HSIL (18 weeks).
Secondary Objectives:
Efficacy:
To evaluate the viral clearance after four 5-day cycles of artesunate ointment To evaluate complete and partial intra-anal response To evaluate complete and partial peri-anal response To evaluate persistence of response throughout the study window
Safety:
To evaluate the safety of artesunate ointment for the treatment of intra-anal HSIL.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Mihaela Plesa
- Phone Number: 440-255-1155
- Email: mplesa@frantzgroup.com
Study Contact Backup
- Name: Ahmad Bayat, MD
- Phone Number: 301-956-2523
- Email: ahmadb@amarexcro.com
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Recruiting
- Anal Dysplasia Clinic MidWest
-
Contact:
- Gary Bucher, MD
- Phone Number: 312-623-2625
- Email: garybuchermd@adcmidwest.com
-
Principal Investigator:
- Gary Bucher, MD
-
Sub-Investigator:
- Emily Miller, APN
-
Contact:
- Agatha Ngwueke
- Phone Number: 3126232625
-
-
New York
-
New York, New York, United States, 10011
- Recruiting
- Laser Surgery Care
-
Principal Investigator:
- Joseph Terlizzi, MD
-
Sub-Investigator:
- Jonathan Baker, PA-C, MPAS
-
Sub-Investigator:
- Shantice Branch, PA-C
-
Contact:
- Taylor Ridley
- Phone Number: 212-242-6500
- Email: tridley@lasersurgerycare.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult men and women age ≥ 18 years
- Capable of informed consent
- Biopsy-confirmed intra-anal high-grade dysplasia (AIN 2, AIN 3, anal HSIL) by HRA.
- Positive anal human papillomavirus (HPV) test.
- Women of childbearing potential agree to use birth control for the duration of the study.
Laboratory values at Screening of:
- Serum alanine transaminase (SGPT/ALT) < 5 x upper limit of normal (ULN)
- Serum aspartate transaminase (SGOT/AST) < 5 x ULN
- Serum Bilirubin (total) < 2.5 x ULN
- Serum Creatinine ≤ 1.5 x ULN
- Electrocardiogram (ECG) with no clinically significant findings as assessed by the Investigator.
- Weight ≥ 50kg
Exclusion Criteria:
- Pregnant and nursing women
- Diagnosis of low-grade anal dysplasia (AIN 1, LSIL), without the concomitant diagnosis of anal HSIL, by HRA
- Concurrent anal, vulvar, cervical, or penile cancer
- HIV-seropositivity
- Currently receiving systemic chemotherapy or radiation therapy for another cancer.
- Patients who are on medical treatment with systemic immunosuppressants or steroids (e.g., active autoimmune disease). Participants using nasal steroid treatments for allergic conditions may participate in the study.
- Concomitant use of strong UGT (Uridine-diphosphate-glucuronosyltransferase) inhibitors
- Concomitant use of imiquimod or 5-fluorouracil (5-FU) for the duration of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo ointment
|
Four 5-day cycles of placebo ointment given at weeks 0, 2, 4, 6
Other Names:
|
Experimental: Artesunate
|
Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete and partial response by week 18
Time Frame: 18 weeks
|
Number of participants with complete and partial response after four 5-day cycles of artesunate ointment
|
18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV clearance
Time Frame: 42 weeks
|
Number of participants who do not have detectable HPV infection
|
42 weeks
|
Complete and partial response after week 18
Time Frame: 30 weeks
|
Number of participants with complete and partial response after week 18
|
30 weeks
|
Complete and partial peri-anal response after intra-anal ointment application
Time Frame: 42 weeks
|
Number of participants who have complete and partial peri-anal response after 4 5-day cycles of intra-anal ointment
|
42 weeks
|
Persistence of response
Time Frame: 42 weeks
|
Number of participants who have complete response and do not have recurrence of anal HSIL
|
42 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of intra-anal artesunate ointment
Time Frame: 42 weeks
|
Number of participants who do not have any drug-related serious adverse events
|
42 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Virus Diseases
- Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Cervical Diseases
- Uterine Diseases
- Disease Attributes
- DNA Virus Infections
- Tumor Virus Infections
- Precancerous Conditions
- Neoplasms, Squamous Cell
- Uterine Cervical Dysplasia
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Carcinoma in Situ
- Carcinoma, Squamous Cell
- Papillomavirus Infections
- Squamous Intraepithelial Lesions of the Cervix
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Anthelmintics
- Schistosomicides
- Antiplatyhelmintic Agents
- Artesunate
- Artenimol
- Artemisinins
- Artemisinin
Other Study ID Numbers
- ART-AIN IIB-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anal High-grade Squamous Intraepithelial Lesion
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedHigh Grade Anal Canal Intraepithelial Neoplasia | High Grade Vulvar Squamous Intraepithelial LesionUnited States
-
David FinchLancashire Teaching Hospitals NHS Foundation TrustNot yet recruitingAnal Intraepithelial Neoplasia | Anal High-grade Squamous Intraepithelial Lesion | Anal HSIL
-
Muğla Sıtkı Koçman UniversityCompletedOxidative Stress | Low Grade Squamous Intraepithelial Lesion | High-Grade Squamous Intraepithelial LesionsTurkey
-
Medtronic - MITGCompletedAnal Intraepithelial Neoplasia (AIN) | High-grade Squamous Intraepithelial Lesions (HSIL)United States
-
National Cancer Institute (NCI)CompletedCervical Cancer | High-grade Squamous Intraepithelial Lesion | Atypical Squamous Cells of Undetermined Significance | Low-grade Squamous Intraepithelial LesionUnited States
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH); amfAR, The Foundation for AIDS ResearchRecruiting
-
Inovio PharmaceuticalsCompletedCervical Dysplasia | Cervical High Grade Squamous Intraepithelial Lesion | HSILUnited States, Spain, Lithuania, Estonia, South Africa, Argentina, Brazil, Finland, Poland, Puerto Rico
-
Baylor College of MedicineMedical University of South Carolina; M.D. Anderson Cancer Center; The University... and other collaboratorsActive, not recruitingAnal High Grade Squamous Intraepithelial LesionUnited States
-
Peking University People's HospitalHangzhou Newhorizon Health Technology Co., Ltd.; Hangzhou Mingze Medical Research... and other collaboratorsRecruitingCervical Cancer | Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Human Papillomavirus Infection | Human Papilloma Virus | Adenocarcinoma in Situ | High-Grade Squamous Intraepithelial Lesions | Cervical Intraepithelial Neoplasia Grade II | Cervical Intraepithelial Neoplasia, Grade III | Atypical... and other conditionsChina
-
National Cancer Institute (NCI)TerminatedHuman Papillomavirus | HPV-16 | High Grade Squamous Intraepithelial LesionUnited States
Clinical Trials on Artesunate ointment
-
Frantz Viral Therapeutics, LLCThe Cleveland ClinicRecruitingVulvar Diseases | HPV Infection | Vulvar HSIL | High Grade Intraepithelial Neoplasia | HPV Disease | Pre-Cancerous Dysplasia | Vin II | Vin III | VIN, Usual Type | VIN 2 of Usual Type | VIN 3 of Usual Type | VIN Grade 2 | VIN Grade 3United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Frantz Viral Therapeutics, LLCActive, not recruitingVulvar Diseases | Vulvar Dysplasia | HPV-Related Vulvar Intraepithelial Neoplasia | Preinvasive Vulvar Disease | Vulva Intraepithelial NeoplasiaUnited States
-
PfizerCompletedDermatitis, AtopicAustralia
-
Yin-ku LinCompletedPsoriasis VulgarisTaiwan
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
PfizerCompletedPlaque Psoriasis | Atopic DermatitisUnited States, Canada, United Kingdom, Japan
-
Serentis Ltd.CompletedAtopic DermatitisGermany, Bulgaria, Finland
-
GlaxoSmithKlineCompleted
-
PfizerCompletedPlaque Psoriasis | Atopic DermatitisUnited States, Australia, Canada, Poland
-
Dermavant Sciences GmbHCompletedAtopic DermatitisCanada, United States